Collection Details : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
This is a US Government work. There are no restrictions on its use. The following represents disclosure information provided by authors of this manuscript. All…
An abstract is unavailable.
Here is your snapshot of all treatment options that the FDA approved in September 2024.
The FREEDOM2 study demonstrates that fedratinib is an effective second-line treatment for myelofibrosis after ruxolitinib failure or intolerance.
Abstract. Financial hardship is a common experience for patients and their families after the diagnosis of a hematologic malignancy and is associated with
Medical experts analyze the exploratory efficacy and safety results for patients with portal vein invasion (Vp4), addressing the challenges in treating this subgroup.
Drs Armstrong and Tawagi discuss the board review plans they followed in the months leading up to their hematology and oncology board exams.
The role of B cells in cancer remains incompletely understood. Three recent publications, including a study by Fitzsimons et al. in this issue of Cancer Cell,…
PURPOSEWe examined the trends in palliative care utilization, racial/ethnic disparities in hospitalization outcomes among adult women with a diagnosis of metastatic breast cancer (MBC), and…
Martin H. Voss, MD, discusses the clinical significance of the phase 3 KEYNOTE-564 trial in clear cell renal cell carcinoma.